The synthesis and human FP receptor binding affinity of 13,14-dihydro prostaglandin F1alpha sulfonamides: potential treatments for osteoporosis.
A novel class of saturated prostaglandin F2alpha sulfonamide analogs have been synthesized and evaluated in the human FP receptor binding assay for potential use in the treatment of osteoporosis. These compounds have been modified at the C1 carboxylic acid moiety and at the C16-C20 region of the prostaglandin. Based on the structure-activity relationships, it was found that at C1, the aryl sulfonamide analogs possessed greater affinity for the hFP receptor when compared to alkyl sulfonamides. When the sulfonamide was introduced into the C16-C20 region (omega chain) of the prostaglandin, a significant reduction in binding was observed. These results are discussed within the framework of a proposed model for the human FP receptor.
Wang
Y
Y
Procter and Gamble Pharmaceuticals, Mason, OH 45040-8006, USA.
Soper
D L
DL
Dirr
M J
MJ
deLong
M A
MA
De
B
B
Wos
J A
JA
D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy; D010024:Osteoporosis / Q000188:drug therapy*; D011982:Receptors, Prostaglandin / Q000378:metabolism*; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis / Q000494:pharmacology
D011982:Receptors, Prostaglandin; D013449:Sulfonamides; D015237:Dinoprost